RCC Clinical Trials

4 recruiting

RCC Trials at a Glance

38 actively recruiting trials for rcc are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Dallas, New York, and Lake Success. Lead sponsors running rcc studies include GI Innovation, Inc., Jinling Hospital, China, and University of Texas Southwestern Medical Center.

Browse rcc trials by phase

Treatments under study

About RCC Clinical Trials

Looking for clinical trials for RCC? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new RCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about RCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 2

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting

Validation of RCC Predicting Model With Emulated-target Trial

Prognostic Cancer ModelRenal Cell Carcinoma (RCC)Prognosis+4 more
Peking University Third Hospital4,700 enrolled1 locationNCT07117227
Recruiting
Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled409 locationsNCT06661720
Recruiting
Phase 1Phase 2

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Not Applicable

CBCT Guided Markerless SBRT for Renal Cell Cancer

Renal Cell Carcinoma (RCC)
Erasmus Medical Center40 enrolled1 locationNCT07402109
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb234 enrolled72 locationsNCT07293351
Recruiting
Phase 3

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Cancer (ccRCC)Renal Cell Carcinoma (Kidney Cancer)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited40 enrolled5 locationsNCT07197580
Recruiting
Phase 1Phase 2

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled7 locationsNCT07300241
Recruiting
Not Applicable

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

Renal Cell Carcinoma (RCC)Nonfunctioning Kidney
Menoufia University60 enrolled1 locationNCT07461090
Recruiting
Not Applicable

Investigation of Lymph Node Biology in Kidney Cancer

Renal Cell Carcinoma (RCC)
Yale University10 enrolled1 locationNCT07038733
Recruiting
Not Applicable

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Urothelial CarcinomaMetastatic Urothelial CarcinomaRenal Cell Carcinoma+9 more
University of Texas Southwestern Medical Center600 enrolled1 locationNCT04623502
Recruiting
Phase 2

Cabozantinib Dose Skipping as an Alternative to Dose Reductions

Renal Cell Carcinoma (RCC)
dr. Tom van der Hulle34 enrolled1 locationNCT07077161
Recruiting
Phase 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

CancerBladder CancerKidney Cancer+3 more
Elephas416 enrolled12 locationsNCT05520099
Recruiting
Not Applicable

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham25 enrolled4 locationsNCT05410509
Recruiting

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Renal Cell CarcinomaCarcinomaKidney Cancer+2 more
Jinling Hospital, China450 enrolled1 locationNCT05917106